Article
Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique.
AIDS research and human retroviruses - 1 Jun 2014
Ismael Nália, Bila Dulce, Mariani Diana, Vubil Adolfo, Mabunda Nedio, Abreu Celina, Jani Ilesh, Tanuri Amilcar
Abstract excerpt
Enfuvirtide was the first fusion inhibitor approved by the Food and Drug Administration (FDA) in 2003 for HIV-1 infection in treatment-experienced patient. It is the first approved antiviral agent to attack the HIV life cycle in its early stages. For HIV fusion to occur, the HR1 and HR2 domains in the gp41 region need to interact. Enfuvirtide is a synthetic peptide that corresponds to 36 amino acids of the HR2,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.